PMID- 36817423 OWN - NLM STAT- MEDLINE DCOM- 20230301 LR - 20230306 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. PG - 993057 LID - 10.3389/fimmu.2023.993057 [doi] LID - 993057 AB - BACKGROUND: Anti-interleukin (IL)-17 biological agents (BAs) have significant efficacy in the treatment of psoriasis and psoriatic arthritis; however, adverse events (AEs) are common, and their safety has not been systematically evaluated. OBJECTIVES: The purpose of this systematic review and meta-analysis was to summarize the number and corresponding rates of AEs caused by anti-IL-17 BAs in patients with psoriasis and psoriatic arthritis to improve clinical decision-making regarding their use. METHODS: PubMed, Embase, Cochrane Library, and Web of Science databases were independently searched by three authors for articles on the treatment of psoriasis with anti-IL-17 BAs that were published before March 1, 2022, and included at least one AE. Dichotomous variables and 95% confidence intervals (CI) were analyzed using R software (version 4.1.3) and the Meta and Metafor software packages. Funnel plots and meta-regression were used to test for the risk of bias, I(2) was used to assess the magnitude of heterogeneity, and subgroup analysis was used to reduce heterogeneity. RESULTS: A total of 57 studies involving 28,424 patients with psoriasis treated with anti-IL-17 BAs were included in the meta-analysis. Subgroup analysis showed that anti-IL-17A (73.48%) and anti-IL-17A/F (73.12%) BAs were more likely to cause AEs than anti-IL-17R BAs (65.66%). The incidence of AEs was as high as 72.70% with treatment durations longer than one year, and long-term use of medication had the potential to lead to mental disorders. Infection (33.16%), nasopharyngitis (13.74%), and injection site reactions (8.28%) were the most common AEs. Anti-IL-17 BAs were most likely to cause type alpha (33.52%) AEs. Type delta AEs (1.01%) were rarely observed. CONCLUSIONS: Anti-IL-17 BAs used for the treatment of psoriasis and psoriatic arthritis caused a series of AEs, but the symptoms were generally mild. CI - Copyright (c) 2023 Wang, Wang, Liu, Hong, Ru, Sun, Chen, Zhang, Lin, Li and Li. FAU - Wang, Jiao AU - Wang J AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Wang, Chunxiao AU - Wang C AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Liu, Liu AU - Liu L AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Hong, Seokgyeong AU - Hong S AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Ru, Yi AU - Ru Y AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Sun, Xiaoying AU - Sun X AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Chen, Jiale AU - Chen J AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Zhang, Miao AU - Zhang M AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Lin, Naixuan AU - Lin N AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Li, Bin AU - Li B AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. AD - Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China. FAU - Li, Xin AU - Li X AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. LA - eng PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20230131 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Interleukin-17) SB - IM MH - Humans MH - *Arthritis, Psoriatic/drug therapy MH - *Psoriasis/drug therapy MH - Interleukin-17/immunology PMC - PMC9928578 OTO - NOTNLM OT - adverse events OT - anti-IL-17 OT - biological agents OT - meta-analysis OT - systematic review COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/24 06:00 MHDA- 2023/03/03 06:00 PMCR- 2023/01/01 CRDT- 2023/02/23 09:36 PHST- 2022/07/13 00:00 [received] PHST- 2023/01/10 00:00 [accepted] PHST- 2023/02/23 09:36 [entrez] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.993057 [doi] PST - epublish SO - Front Immunol. 2023 Jan 31;14:993057. doi: 10.3389/fimmu.2023.993057. eCollection 2023.